Qube Research & Technologies LTD Protalix Bio Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
A detailed history of Qube Research & Technologies LTD transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 36,438 shares of PLX stock, worth $61,944. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,438
Previous 121,030
69.89%
Holding current value
$61,944
Previous $141,000
73.76%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PLX
# of Institutions
49Shares Held
3.54MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$1.63 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$739,8620.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$635,3860.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$566,3900.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$459,0000.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $84.6M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...